The Fibroblast Growth Factor Binding Protein (FGF-BP, GenBank #NP_005121) is a secreted protein that mobilizes FGFs from the extracellular matrix, protects them from degradation, and enhances their biologic activity. Several previous studies reported that FGF-BP is an early response gene upregulated during tissue repair processes including wound healing and atherogenesis. Here we analyzed whether FGF-BP expression is impacted by spinal cord injury and could have an effect on neuronal cell viability. Immunohistochemical and in situ hybridization studies revealed a dramatic upregulation of FGF-BP protein and mRNA levels following unilateral hemisection and contusion injury of adult rat spinal cord. In spinal cord sections of laminectomized rats, increased FGF-BP expression was observed in the fibers and cell bodies ipsilateral to the lesion site but was absent in the uninjured spinal cord tissue contralateral to the lesion. Increased expression of FGF-BP was observed at all post-injury time points examined with peak levels occurring at day 4, a time when injury-induced increased levels of FGF2 have also been reported to be maximal. Moreover, using PC12 cells as a neuronal model, we observed that exogenous FGF-BP increased the capacity of FGF2 to stimulate neurite outgrowth and to increase cell survival. At the molecular level, FGF-BP enhanced FGF2-induced protein tyrosine phosphorylation and AKT/PKB activation. Collectively, these results suggest that FGF-BP is an early response gene after spinal cord injury and its upregulation in regenerating spinal cord tissue may provide a molecular mechanism for enhancing the initial FGF2-mediated neurotrophic effects occurring after such tissue damage.
INTRODUCTION
The family of fibroblast growth factors (FGFs) encompasses, to date, over 20 distinct polypeptides that play pivotal roles in several biological processes, such as embryonic development (66) , angiogenesis (56) , and tumorigenesis (22) . Several studies have found that multiple FGFs, but predominantly FGF1 and FGF2, are expressed in the central nervous system (CNS) and are key regulators of CNS development and functions (13, 27, 28, 75) . Interestingly, although both FGF1 and FGF2 are highly expressed in developing brain and adult CNS, their cellular localization patterns are different. Whereas FGF2 accumulates in both neuronal and nonneuronal cells, FGF1 is found primarily in neurons (13, 59) . Evidence of FGF1 and -2 mitogenic and neurotrophic activities includes their ability to enhance the survival and outgrowth of a various neuronal cell types, such as neocortical, hippocampal, cerebellar, dopaminergic, spinal cord and sensory neurons isolated from adult CNS (13, 30, 44, 54) . They also stimulate neuronal cell fate determination (3) , migration and differentiation (59) . Moreover, both FGF1 and FGF2
and their cognate receptors are upregulated after experimental central and peripheral nervous system injury (20, 24, 32, 43, 46) . The ability of FGFs to act as potent neurotrophic factors has been extensively demonstrated. FGF2 prevents axotomy-induced death of glutamatergic neurons (53) . Administration of FGF2 in vivo improves rat sensorimotor functions, reduces focal ischemia-induced infarct size (40) , stimulates functional recovery of rats subjected to motor cortex lesion (48) and promotes rat hippocampal cell survival upon kainic acid-induced seizure (42) . Proliferation and differentiation of hippocampal cells after seizure or cerebral ischemia failed to occur in FGF2 -/-mice (18, 76) . Similarly, rats treated with anti-FGF2 neutralizing antibody displayed decreased cholinergic sprouting following the removal of hippocampal entorhinal cortical inputs (18) . Moreover, various FGFs, such as FGF1, FGF2, FGF4, FGF5, and FGF9, have been shown to be highly expressed in and promote survival of spinal motoneurons (13, 15, 26, 31, 33, 70) upon axotomy or spinal cord injury (SCI) (9, 39, 45, 64, 65) . In addition, FGF2 knock-out mice display neuronal defects in the cervical spinal cord region (14) . These studies altogether suggest that endogenous FGF is likely to help rescue injured neurons and to promote nerve regeneration.
FGF1 and FGF2 lack a signal peptide required for cellular secretion, nevertheless they are found immobilized on extracellular matrix (ECM) heparan sulfate proteoglycans (47, 55) . One mechanism for mobilizing FGFs from ECM requires heparinases or other glycosaminoglycandegrading enzymes (7, 55, 61, 72) . An independent mechanism involves a secreted FGF binding protein (FGF-BP) that functions as an extracellular chaperone for locally-stored FGFs. Here we analyze the FGF-BP protein initially named HBp17 (FGFBP1, Genbank # NP_005121). Studies from our and other laboratories have indicated that FGF-BP is a binding partner for FGF1, FGF2, FGF7, FGF10 and FGF22 (5, 49, 62) and we have delineated the FGF-BP C-terminus as the interaction domain for FGF2 (74) . Moreover, FGF-BP is likely to complement the role of heparan sulfate in mediating FGF-dependent signaling and mitogenesis (57) . It has been shown that FGF-BP binds to perlecan, and heparan sulfate or heparinoids can compete with FGF-BP for binding to FGF2 in vitro, thereby supporting the role for FGF-BP as a chaperone molecule for FGFs immobilized in the extracellular matrix (ECM) (49, 62) . Furthermore, FGF-BP protects FGF proteins from acid inactivation (73) and enhances their biochemical and biological activity (1, 57, 62) . FGF-BP is overexpressed in a number of human cancers (1, 63) . FGF-BP mRNA and protein are dramatically upregulated during early stages of colon and pancreatic cancer (i.e. dysplastic lesions) and this overexpression is sustained throughout cancer progression and metastasis (58, 63) . In addition, FGF-BP appears to be upregulated during preneoplastic stages of carcinogen-treated human skin, concomitantly with an increase in angiogenesis (37). The biologic significance of FGF-BP expression was revealed ribozyme-mediated depletion of endogenous FGF-BP from human colon and squamous cell carcinoma cell lines that resulted in decreased tumor growth and angiogenesis in vivo (10) .
A potential role for FGF-BP as an early response gene for nonmalignant conditions is suggested by recent observations of a transient upregulation of FGF-BP in wounded skin (5, 37) , as well as during the regeneration of renal tubular epithelial cells in pediatric patients affected by HIV infection associated with hemolytic uremic syndrome (41, 57) . Hence, it is tempting to speculate that FGF-BP plays crucial early roles in the repair of tissue with aberrant FGF activity, by enhancing FGF-mediated angiogenesis and therefore accelerating wound healing or contributing to the healing of renal capillaries and tubules. These findings were extended to another nonmalignant condition, when FGF-BP was found to be upregulated at both protein and mRNA levels in the aorta of a mouse model susceptible to early atherogenesis (51).
Based on these observations, we investigated the regulation of FGF-BP expression during nerve injuries and studied a potential contribution to the repair process reflected in cell survival and neurite outgrowth. Here we show that FGF-BP is upregulated at both protein and mRNA levels following contusion injury or unilateral hemisection of the adult rat spinal cord, with elevated expression restricted to the fibers and cell bodies ipsilateral, but not contralateral to the lesion sites. We also observed that FGF-BP synergistically enhances FGF2-induced neurite outgrowth and FGF2-dependent survival of rat pheochromocytoma cells (PC12) that served as a neuronal model system. Finally, we show that these cells, when co-stimulated with exogenous FGF-BP and suboptimally effective concentrations of FGF2, exhibit a differential protein tyrosine phosphorylation profile as well as an enhancement of AKT activation.
MATERIALS AND METHODS
Expression and Purification of recombinant FGF-BP. Expression and purification of recombinant human FGF-BP from Sf-9 insect cells was described elsewhere (62) . Survival Assay. PC12 cells were seeded in 6-well plates at a density of 10 6 cells per well. After overnight growth in complete medium, the cells were washed twice with phosphate-buffered saline (PBS), and maintained for 24 hours in serum-free medium containing recombinant FGF-BP (6 ng/ml) and/or human recombinant FGF2 (5 ng/ml). Control cells were left untreated. Apoptosis was measured by flow cytometry with the aid of TACS Annexin V-FITC (Trevigen, Gaithersburg, MD), as indicated by the manufacturer.
Western blot and phosphorylation studies. Subconfluent PC12 cells were serum-starved for 16 hours in DMEM medium and then stimulated with recombinant FGF-BP (3 ng/ml) and/or human recombinant FGF2 (1 or 10 ng/ml) for 15 minutes at 37 o C. Cell lysates were prepared as previously described (62) . 50 µg of total cellular protein were separated by 4-10% gradient SDSpolyacrylamide gel electrophoresis (PAGE) and transferred onto PVDF membranes. Immunoblot studies for identifying tyrosine phosphorylated protein were performed with a monoclonal antiphosphotyrosine antibody (clone 4G10) (Upstate Biotechnology, Lake Placid, NY) as previously described (62) . Immunoblot studies for anti phospho-and total AKT as well as for phospho MAPK were performed with the respective rabbit polyclonal antibodies (Cell Signaling, Danvers, MA) (1:1000 dilution). Actin was detected with mouse anti-actin monoclonal antibody (1:1000 dilution) (Chemicon International, Temecula, CA). Visualization was performed by enhanced chemiluminescence (SuperSignal West Pico Chemiluminescent) (Pierce, Rockford, IL) using horseradish peroxidase-linked donkey anti-mouse or anti-rabbit immunoglobulin G as a secondary antibody (Amersham Biosciences).
Experimental Spinal Cord Injury. Seven adult female Sprague-Dawley rats (Zivic-Miller, Allison
Park, PA; 200-250 g) were deeply anesthetized with a mixture of ketamine (Aveco; Ketaset; 40 mg kg -1 ) and xylazine (Haver, Pompun; 6.7 mg kg -1 ). Laminectomy was performed at spinal C 4-5 , and a midline dural incision was made. Thereafter, a right unilateral hemisection lesion cavity of 3 mm in length was created by aspiration. After hemostasis was obtained, the lesion site was filled with Gelfoam (Amersham Pharmacia Biotech, Piscataway, NJ) and the dural incision was closed with 10-0 sutures. The animals were given a subcutaneous injection of penicillin (100,000 U) and an intraperitoneal injection of isotonic saline, following a treatment buprenorphine as an analgesic and with penicillin procaine G (3000 U daily) for the first week following surgery.
Tissue specimens for immunocytochemical analysis were obtained at 2 (n=3), 4 (n=2), and 7 (n=2) days post-injury. To perform contusion injury, laminectomy was performed at spinal cord level T 8 . Tissue specimens were collected at 1, 4, and 7 days post-injury (n=3 per time point).
Intermediate grade contusion injuries were made with the NYU electromechanical impact device (4) .
Immunohistochemistry.
Using the lesion site as the central point, a 14-mm segment of injured spinal cord was removed, fixed in formalin overnight at 4 o C, and embedded in paraffin. Immunohistochemical analysis on paraffin-embedded spinal cord tissue sections (10 µm) and quantitation was performed as described (63) . Detection of rat FGF-BP was obtained by incubating the tissues with a rabbit anti-human FGF-BP polyclonal antibody (2) for 12 hours at 4°C, followed by incubation with a biotinylated goat anti-rabbit secondary antibody (1:500) (Vector Laboratories, Burlingame, CA) for 1 hr at room temperature. Colorimetric reaction was performed with the Vectastain ABC kit (Vector Laboratories, Burlingame, CA), according to the manufacturer's instructions.
In Situ Hybridization. In situ hybridization analyses were carried out as previously described (29, 63) . The digoxigenin-labeled riboprobes were generated from bases 1296 to 1622 of the rat FGF-BP full-length coding sequence (2) subcloned into pRc/CMV 5.5 vector (Invitrogen Corporation, Carlsbad, CA). The vector was linearized with either Hind III or Xba I in order to generate antisense and sense probes, respectively. 
RESULTS

Expression of FGF-BP in adult rat spinal cords after injury.
In previous work (2) the expression of FGF-BP protein was detecteable in some rat adult nervous system tissues by immunohistochemical analysis. Strong immunostaining was detected mainly in the eye, particularly in the retina, outer plexiform layer, ciliary body, rods and cones. In the brain, FGF-BP was found in the choroids plexus and in the Purkinje cells of the cerebellar cortex. In contrast, low or undetectable FGF-BP protein levels were found in most other tissues. FGF-BP is an early response gene involved in the repair of injuries to multiple types of tissues, such as skin and kidney (37, 57). We conjectured that FGF-BP might also be regulated during injury to the nervous system. Most interestingly, FGFs were reported upregulated after spinal cord injury (SCI) (45, 46) and we thus used injury to adult rat spinal cord as a model system. In a first experimental series, spinal contusion was performed on adult rats and the effect on FGF-BP protein levels was examined by immunohistochemical analysis. Spinal cord tissue contralateral to the lesion sites was used as the negative control. Although no FGF-BP staining was detected in the control tissues, strong FGF-BP immunoreactivity was observed in discrete populations of damaged fibers at 1, 4, and 7 days following injury, with peak levels occurring at 4 days postinjury ( Fig. 1) . Interestingly, this post-injury time course of FGF-BP expression is similar to that reported for FGF2, which was highest at four days after SCI, but predominantly detected in a different cell type (astrocytes) (45).
A second type of SCI, unilateral spinal cord hemisection, was also used to investigate the post-traumatic regulation of FGF-BP protein accumulation. These lesions were also accompanied by dramatically upregulated FGF-BP protein levels. This upregulation occurred in the proximal endbulbs of severed white matter tracts located immediately rostral and caudal to the lesion site Fig. 2A and 2C ; DRG not depicted).
To detect FGF-BP mRNA expression in laminectomized rats, in situ hybridization was performed. Results similar to the protein expression pattern were found: an antisense probe detected upregulation of FGF-BP mRNA primarily in large motoneurons in the ventral grey matter and in the large sensory neurons within the DRG ipsilateral (Fig. 3A) , but not contralateral ( Fig. 3B) to the lesion. The specificity of these positive signals was demonstrated by absence of detectable staining when a control, sense-strand probe was used ( Fig. 3C ). Consistent with our observations, Koshinaga and colleagues (36) found increased amounts of FGF1 and FGF2 protein in motoneurons of injured rat spinal cord.
Effect of FGF-BP on FGF2-induced neurite outgrowth
FGF-BP enhances FGF-induced growth of various cell lines, including human tumor cells
and murine fibroblasts and endothelial cell lines (10, 11, 38, 57, 62) . In order to examine the ability of FGF-BP to affect neuronal cell responses to FGF2 we used rat pheochromocytoma cells (PC12) as a model. PC12 cells are the immortalized counterpart of rat adrenal chromaffin cells, which are derived from neural crest progenitors (25) and can be differentiated towards neuronal cells by addition of exogenous growth factors. PC12 cells produce FGF2 protein and mRNA (23) and respond to exogenous FGF by growing neuritic processes (60, 68) . Consistent with previous reports, we observed that PC12 cells were poorly adherent and grew only a few short filopodial extensions when cultured for 8 days in serum-free medium (Fig. 4A; ctrl) . Nerve growth factor (NGF) caused these cells to grow long extensions ( Fig. 4A; NGF) , while FGF2 caused cells to grow shorter extensions that increased in number with increasing doses of FGF2 ( Fig. 4A; FGF2 at 5 and 50 ng/ml, respectively). The effect of increasing FGF-BP doses on the FGF2-induced neurite outgrowth is shown in Figure 4B 
Effect of FGF-BP on FGF2-dependent survival of PC12 cells.
PC12 cells undergo apoptosis after serum deprivation and various molecules, such as nitric oxide (35) , NGF, and FGF2 can act as survival factors (71) . To investigate whether FGF-BP can enhance the survival effect of FGF2 in serum-deprived PC12 cells, apoptotic rates were evaluated 24 hours after serum withdrawal. As shown in Figure 5 , both FGF-BP alone and a suboptimal dose of FGF2 alone caused a modest, non significant, rescue from apoptosis. In contrast, the synergistic effect of FGF-BP and FGF2 resulted in significantly fewer apoptotic cells ( >50% reduction, p<0.01). Thus, FGF-BP can enhance FGF2-mediated anti-apoptotic effects to levels comparable to those obtained by serum (a 70% reduction, p<0.01 versus the no serum control). These data show that FGF-BP can positively modulate FGF2 biological effects in neuroectodermal cells.
Effects of FGF-BP on FGF2-induced signaling.
Several growth factors trigger downstream signaling cascades after they engage their cognate tyrosine-kinase receptors, such as ERK1/2 MAP kinase, p38, JNK, and PI3-K/AKT and the associated pathways (16, 55) . In addition to NGF receptors, PC12 cells express receptors for FGF, epidermal growth factor (EGF) and insulin that can trigger receptor type-dependent biological responses following their activation (12, 71) . Since FGF-BP acts as a chaperone molecule able to enhance FGF2-mediated biochemical responses in vitro in various cell lines (57, 62) , we sought to investigate whether FGF-BP could also affect FGF2-mediated signaling in PC12 cells. Serum-starved PC12 cells were treated with either recombinant FGF-BP or FGF2 or both, and phospho-tyrosine levels determined by Western blot analysis using a phospho-tyrosine antibody. As shown in Figure 6 respectively. Comparable levels of tyrosine phosphorylation were observed with a 10-fold higher concentration of FGF2 alone (10 ng/ml) and could not be further increased with FGF-BP costimulation. The nature of these two bands has not been determined but is currently under investigation. Since PI3-K can be upregulated in FGF2-treated PC12 cells (34) , and because the activation of AKT promotes FGF2-mediated survival of PC12 and embryonic rat hippocampal cells (17), we also tested the effect of FGF-BP on FGF2-induced AKT phosphorylation.
Stimulation of PC12 cells with increasing concentrations of FGF2 resulted in a dose-dependent
increase in pAKT. Consistent with the protein tyrosine phosphorylation pattern described above, the ability of FGF-BP to enhance AKT phosphorylation was observed with low doses of FGF2 (1 ng/ml). Immunoblot analysis of p38 (not shown) and ERK1/2 MAP kinase phosphorylation (Fig.   6B ) did not reveal a synergistic effect of FGF-BP on FGF2 stimulation under these experimental conditions. Collectively, these results indicate that FGF-BP acts a positive modulator of FGF2mediated signaling in PC12 cells which leads to increased PC12 survival and differentiation.
DISCUSSION
FGF-BP plays a significant role in tumor growth and malignant transformation (1, 10, 11, 63) . In addition, tissue-specific regulation of FGF-BP gene expression during embryonic development (2, 38) and skin wound healing (37) suggests a role for FGF-BP in these biological processes.
Based on these earlier studies, we examined FGF-BP expression during two different kinds of spinal cord injuries (SCI). Since FGFs, acting as potent neurotrophic factors, appear to have a significant role in the repair and recovery processes following spinal cord injuries (45, 46), we hypothesized that FGF-BP also may be involved. Our previous data indicate that FGF-BP is highly expressed during early embryonic spinal cord development (2), but becomes downregulated in that tissue after birth (2, 11, 38) . Our present immunohistochemical analyses are consistent with these earlier reports since FGF-BP protein is undetectable in the spinal cords of adult rats. Here we show for the first time that FGF-BP is dramatically upregulated in the spinal cord of laminectomized rats. Remarkably, the time course and pattern of FGF-BP upregulation observed here parallels the profile of FGF upregulation observed in the injured rat spinal cord (45). Indeed, Mocchetti and colleagues (45) examined the expression of FGF2 in the adult rat spinal cord at the same post-injury time points (1, 4, and 7 days) and reported that FGF2 expression was highest at 4 days post-injury. Interestingly, we also observed the highest levels of FGF-BP protein at 4 days following spinal cord injury. Although having similar temporal patterns of upregulation after similar kinds of SCI, FGF-BP and FGF2 have very different spatial profile. While FGF2 was mainly found in astrocytes (46) , our data indicate that FGF-BP protein is found primarily in damaged neurons. In situ hybridization analysis indicates that FGF-BP transcript is abundantly expressed in the large motoneurons in the ventral grey matter, suggesting that these neurons synthesize most or all of the damage-induced FGF-BP. Since FGF2 and FGF-BP have similar expression time courses, it is tempting to speculate that the localization and upregulation of FGF-BP expression by injured neurons may accelerate the release of FGF2 from its glial source. Increased mobilization of FGF2 by FGF-BP may result in stronger effects on neighboring neurons, thus facilitating spinal cord repair and recovery and therefore enhancing FGF2 neurotrophic activity.
Interestingly, previous reports indicate that upregulation of FGF2 following SCI not only precedes upregulation of the p75 subunit of the nerve growth factor receptor (p75), but may in fact also induce its upregulation (6, 19, 21, 46) . Most importantly, p75 is a key molecule playing a role during later stages of injured spinal cord repair and regeneration (46) . Therefore, it is tempting to speculate that FGF-BP-mediated enhancement of FGF2 neurotrophic functions following SCI is likely to be one of the initial events during the phase of tissue repair. Consistent with our current findings, FGF-BP was found to be an early response gene dramatically upregulated during other tissue repair events, such as wound healing (5, 37) and regeneration of renal tubular epithelial cells in pediatric patients affected by HIV infection associated with hemolytic uremic syndrome (41, 57) .
To ascertain the physiological relevance of our in vivo observations, we sought to investigate the potential role of FGF-BP on cultured neuronal cell growth and survival, in vitro processes in which the neurotrophic activity of FGF is well established (see Introduction). We report the first evidence indicating that FGF-BP can enhance FGF2-induced neuronal cell differentiation and survival, using a rat pheochromocytoma PC12 cell model. PC12 cells are a useful model for studying neuritic outgrowth in response to neurotrophins (67) because the neural crest origin of these immortalized adrenal chromaffin cells allows them to respond to FGF by elaborating a sympathetic neuron-like phenotype (60, 68) . Consistent with previous reports, we observed that FGF2 is capable of inducing both neurite outgrowth and survival of PC12 cells upon serum deprivation in a dose-dependent manner (71) . Although FGF-BP alone was capable of inducing only modest neurite outgrowth and survival of PC12 cells, its greatest effects were observed when PC12 cells were treated simultaneously with FGF-BP and low doses of FGF2. A synergistic relationship between FGF2 and FGF-BP can also be demonstrated at the signal transduction level as evidenced by the differential phosphoprotein profile and activation of the AKT pathway. Albeit our data appear inconsistent with findings by Wert et al. (71) , who reported that activation of the Ras/MAPK pathway, but not the PI3-K/AKT pathway, appeared to mediate the effect of FGF2 on the survival of serum-deprived PC12 cells, they corroborate that the AKT pathway promotes FGF2-mediated antiapoptotic effects in PC12 cells, in H19-7 embryonic rat hippocampal cells (17) and in breast cancer cell lines (69) . Most importantly, AKT activation has been linked with neuronal cell survival as well as axonal regeneration in response to traumatic brain injury (8, 50, 52) . 
